1. S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study. (11th November 2022) Authors: Maspero, JF; Antila, MA; Jean, N; Deschildre, A; Bacharier, LB; Altincatal, A; Rimington, T; Laws, E; Akinlade, B; Radwan, A; Jacob-Nara, JA; Deniz, Y; Rowe, PJ; Lederer, DJ; Hardin, M Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S127 Relation between change in type 2 biomarker levels and efficacy outcomes in patients with asthma treated with dupilumab. (11th November 2022) Authors: Pavord, ID; Deniz, Y; Casale, T; Corren, J; FitzGerald, JM; Altincatal, A; Gall, R; Pandit-Abid, N; Radwan, A; Jacob-Nara, JA; Rowe, PJ; Busse, WW Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗